Clinical outcomes in vaccinated and unvaccinated patients with COVID-19: a population-based analysis

被引:0
作者
Papaioannou, O. [1 ]
Karampitsakos, T. [1 ]
Tsiri, P. [1 ]
Sotiropoulou, V. [1 ]
Koulousousa, E. [1 ]
Tasiopoulos, P. [1 ]
Schinas, G. [2 ]
Katsaras, M. [1 ]
Zarkadi, E. [1 ]
Malakounidou, E. [1 ]
Georgiopoulou, V. [1 ]
Sampsonas, F. [1 ]
Spyridonidis, A. [3 ]
Akinosoglou, K. [2 ]
Marangos, M. [2 ]
Tzouvelekis, A. [1 ]
机构
[1] Univ Hosp Patras, Dept Resp Med, Patras, Greece
[2] Univ Hosp Patras, Dept Internal Med, Patras, Greece
[3] Univ Hosp Patras, Dept Hematol, Patras, Greece
关键词
Vaccination; COVID-19; Cumulative incidence; Hospitalization risk; Mortality; Booster dose; BNT162B2;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: Real-life data for vaccination against COVID-19 are sorely needed. This was a population-based analysis aiming at investigating the hospitalization risk for COVID-19 of 98,982 subjects and compare features of vaccinated and unvaccinated patients. PATIENTS AND METHODS: Hospitalized patients with COVID-19 between 01/07/2021 and 11/02/2022 were included in the study. RESULTS: 582 patients were included in the analysis [males: 58.6% (n=341), vaccinated patients: 28.5% (n=166), unvaccinated patients: 71.5% (n=416)]. Median age of vaccinated patients was significantly higher compared to median age of unvaccinated [74.0 (95% CI: 72.0-77.0) vs. 59.0 (95% CI: 57.0-62.0), p=0.0001]. Mean latency time (+/- SD) from the second dose to hospitalization was 5.7 +/- 2.6 months. Between 01/07/2021 and 01/12/2021, unvaccinated subjects had higher risk for hospitalization compared to vaccinated [HR: 2.82, 95% CI: 2.30-3.45, p < 0.0001]. Between 02/12/2021 and 11/02/2022, unvaccinated subjects presented with higher risk for hospitalization than subjects that had received booster dose [HR: 2.07, 95% CI: 1.44-2.98, p=0.005], but not than subjects that got two doses. Median value of hospitalization days was higher in unvaccinated patients compared to vaccinated [7.0 (95% CI: 7.0-8.0) vs. 6.0 (95% CI: 5.0-7.0), p=0.02]. Finally, age-adjusted analysis showed that hospitalized unvaccinated patients presented with significantly higher mortality risk compared to hospitalized vaccinated patients [HR: 2.59, 95% CI: 1.69-3.98, p < 0.0001]. CONCLUSIONS: Vaccination against COVID-19 remains the best way to contain the pandemic. There is an amenable need for booster dose during the omicron era.
引用
收藏
页码:7705 / 7712
页数:8
相关论文
共 31 条
[1]   Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar [J].
Abu-Raddad, L. J. ;
Chemaitelly, H. ;
Ayoub, H. H. ;
AlMukdad, S. ;
Yassine, H. M. ;
Al-Khatib, H. A. ;
Smatti, M. K. ;
Tang, P. ;
Hasan, M. R. ;
Coyle, P. ;
Al-Kanaani, Z. ;
Al-Kuwari, E. ;
Jeremijenko, A. ;
Kaleeckal, A. H. ;
Latif, A. N. ;
Shaik, R. M. ;
Abdul-Rahim, H. F. ;
Nasrallah, G. K. ;
Al-Kuwari, M. G. ;
Butt, A. A. ;
Al-Romaihi, H. E. ;
Al-Thani, M. H. ;
Al-Khal, A. ;
Bertollini, R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (19) :1804-1816
[2]   Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants [J].
Abu-Raddad, Laith J. ;
Chemaitelly, Hiam ;
Butt, Adeel A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (02) :187-189
[3]  
Andrews N, 2022, NEW ENGL J MED, V386, P1532, DOI [10.1016/S1473-3099(22)00309-7, 10.1056/NEJMoa2119451]
[4]   BNT162b2 Vaccine Booster and Mortality Due to Covid-19 [J].
Arbel, Ronen ;
Hammerman, Ariel ;
Sergienko, Ruslan ;
Friger, Michael ;
Peretz, Alon ;
Netzer, Doron ;
Yaron, Shlomit .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (26) :2413-2420
[5]   Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].
Baden, Lindsey R. ;
El Sahly, Hana M. ;
Essink, Brandon ;
Kotloff, Karen ;
Frey, Sharon ;
Novak, Rick ;
Diemert, David ;
Spector, Stephen A. ;
Rouphael, Nadine ;
Creech, C. Buddy ;
McGettigan, John ;
Khetan, Shishir ;
Segall, Nathan ;
Solis, Joel ;
Brosz, Adam ;
Fierro, Carlos ;
Schwartz, Howard ;
Neuzil, Kathleen ;
Corey, Larry ;
Gilbert, Peter ;
Janes, Holly ;
Follmann, Dean ;
Marovich, Mary ;
Mascola, John ;
Polakowski, Laura ;
Ledgerwood, Julie ;
Graham, Barney S. ;
Bennett, Hamilton ;
Pajon, Rolando ;
Knightly, Conor ;
Leav, Brett ;
Deng, Weiping ;
Zhou, Honghong ;
Han, Shu ;
Ivarsson, Melanie ;
Miller, Jacqueline ;
Zaks, Tal .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416
[6]   Protection against Covid-19 by BNT162b2 Booster across Age Groups [J].
Bar-On, Yinon M. ;
Goldberg, Yair ;
Mandel, Micha ;
Bodenheimer, Omri ;
Freedman, Laurence ;
Alroy-Preis, Sharon ;
Ash, Nachman ;
Huppert, Amit ;
Milo, Ron .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (26) :2421-2430
[7]   Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study [J].
Barda, Noam ;
Dagan, Noa ;
Cohen, Cyrille ;
Hernan, Miguel A. ;
Lipsitch, Marc ;
Kohane, Isaac S. ;
Reis, Ben Y. ;
Balicer, Ran D. .
LANCET, 2021, 398 (10316) :2093-2100
[8]   Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant [J].
Bernal, Jamie Lopez ;
Andrews, Nick ;
Gower, Charlotte ;
Gallagher, Eileen ;
Simmons, Ruth ;
Thelwall, Simon ;
Stowe, Julia ;
Tessier, Elise ;
Groves, Natalie ;
Dabrera, Gavin ;
Myers, Richard ;
Campbell, Colin N. J. ;
Amirthalingam, Gayatri ;
Edmunds, Matt ;
Zambon, Maria ;
Brown, Kevin E. ;
Hopkins, Susan ;
Chand, Meera ;
Ramsay, Mary .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (07) :585-594
[9]  
Conlon Anne Marie, 2022, Nature, DOI 10.1038/d41586-022-00201-8
[10]   Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection [J].
Dan, Jennifer M. ;
Mateus, Jose ;
Kato, Yu ;
Hastie, Kathryn M. ;
Yu, Esther Dawen ;
Faliti, Caterina E. ;
Grifoni, Alba ;
Ramirez, Sydney, I ;
Haupt, Sonya ;
Frazier, April ;
Nakao, Catherine ;
Rayaprolu, Vamseedhar ;
Rawlings, Stephen A. ;
Peters, Bjoern ;
Krammer, Florian ;
Simon, Viviana ;
Saphire, Erica Ollmann ;
Smith, Davey M. ;
Weiskopf, Daniela ;
Sette, Alessandro ;
Crotty, Shane .
SCIENCE, 2021, 371 (6529) :587-+